4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors
    1.
    发明授权
    4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors 失效
    4-巯基吡咯烷衍生物作为法呢基转移酶抑制剂

    公开(公告)号:US06541491B1

    公开(公告)日:2003-04-01

    申请号:US09725964

    申请日:2000-11-30

    IPC分类号: A61K3140

    摘要: Pharmaceutical compositions comprising an inhibitor of ras farnesylation of formula (I) wherein, R1 is for example H and further values as defined in the specification; R2 is for example H and further values as defined in the specification; R3 is for example H or a substituent having values as defined in the specification; p is 0-3 in which R3 values can be the same or different; L is a linking moiety for example —CO—NH2— and further values as defined in the specification; A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms where the heteroatoms are independently selected from O, N and S; or a —S—S-dimer thereof when R2=H; or an enantiomer, diastereoisomer, pharmaceutically acceptable salt, prodrug or solvate thereof together with a pharmaceutically acceptable diluent or carrier. A particular use is cancer therapy.

    摘要翻译: 包含式(I)的ras法呢基酯化抑制剂的药物组合物,其中R1为例如本说明书中定义的其它值; R2是例如H和说明书中定义的其它值; R3是例如H或具有本说明书中定义的值的取代基; p为0-3,其中R3值可以相同或不同; L是例如-CO-NH 2的连接部分和如说明书中定义的进一步的值; A选自苯基; 萘基; 含有多达5个杂原子的5-10元单环或双环杂芳基环,其中杂原子独立地选自O,N和S; 或其-S-S-二聚体时,R 2 = H; 或其对映体,非对映异构体,药学上可接受的盐,前药或溶剂合物以及药学上可接受的稀释剂或载体。 一个特别的用途是癌症治疗。

    4-Mercaptopyrrolidine derivatives as farnesyl transferase inhibitors
    2.
    发明授权
    4-Mercaptopyrrolidine derivatives as farnesyl transferase inhibitors 失效
    4-巯基吡咯烷衍生物作为法呢基转移酶抑制剂

    公开(公告)号:US06232338B1

    公开(公告)日:2001-05-15

    申请号:US09011135

    申请日:1998-02-03

    IPC分类号: A61K3140

    摘要: Pharmaceutical compositions comprising an inhibitor of ras farnesylation of formula (I) wherein, R1 is for example H and further values as defined in the specification; R2 is for example H and further values as defined in the specification; R3 is for example H or a substituent having values as defined in the specification; p is 0-3 in which R3 values can be the same or different; L is a linking moiety for example —CO—NH2— and further values as defined in the specification; A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms where the heteroatoms are independently selected from O, N and S; or a —S—S— dimer thereof when R2=H; or an enantiomer, diastereoisomer, pharmaceutically acceptable salt, prodrug or solvate thereof together with a pharmaceutically acceptable diluent or carrier. A particular use is cancer therapy.

    摘要翻译: 包含式(I)的ras法呢基酯化抑制剂的药物组合物,其中R1为例如本说明书中定义的其它值; R2是例如H和说明书中定义的其它值; R3是例如H或具有本说明书中定义的值的取代基; p为0-3,其中R3值可以相同或不同; L是例如-CO-NH 2的连接部分和如说明书中定义的进一步的值; A选自苯基; 萘基; 含有多达5个杂原子的5-10元单环或双环杂芳基环,其中杂原子独立地选自O,N和S; 或其-S-S-二聚体时,R 2 = H; 或其对映体,非对映异构体,药学上可接受的盐,前药或溶剂合物以及药学上可接受的稀释剂或载体。 一个特别的用途是癌症治疗。